Bio-Techne (TECH) Stock Price
Bio-Techne Price
Revenue has compounded at 9.3% per year over the past 19 years to 1.22 B USD. Earnings per share have grown at 4.1% per year over the last 19 years. Bio-Techne's net margin stands at 15.0%, down from 24.6% several years earlier. Bio-Techne currently offers a dividend yield of about 0.44%. The payout ratio is around 40% of earnings. The dividend has grown at 1.4% per year over the past 18 years. Analysts set a median price target of 71.40 USD, implying 1.2% below the current price. Of 23 analysts, 18 rate the stock a buy — an overall Buy consensus. The stock trades about 67% above its 52-week low.
Bio-Techne stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Bio-Techne over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bio-Techne stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bio-Techne's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Bio-Techne Price |
|---|---|
| 9/2/2026 | 72.30 USD |
| 9/1/2026 | 72.18 USD |
| 8/31/2026 | 72.32 USD |
| 8/28/2026 | 72.36 USD |
| 8/27/2026 | 72.47 USD |
| 8/26/2026 | 72.38 USD |
| 8/25/2026 | 72.33 USD |
| 8/24/2026 | 72.38 USD |
| 8/21/2026 | 72.32 USD |
| 8/20/2026 | 72.28 USD |
| 8/19/2026 | 72.49 USD |
| 8/18/2026 | 72.41 USD |
| 8/14/2026 | 72.40 USD |
| 8/13/2026 | 72.17 USD |
| 8/12/2026 | 72.23 USD |
| 8/11/2026 | 72.15 USD |
| 8/10/2026 | 72.12 USD |
| 8/7/2026 | 72.29 USD |
| 8/6/2026 | 71.90 USD |
| 8/5/2026 | 72.07 USD |
| 8/4/2026 | 72.14 USD |
| 8/3/2026 | 72.14 USD |
| 7/31/2026 | 72.09 USD |
| 7/30/2026 | 72.03 USD |
| 7/29/2026 | 72.11 USD |
| 7/27/2026 | 71.80 USD |
| 7/23/2026 | 71.77 USD |
| 7/22/2026 | 71.78 USD |
| 7/21/2026 | 71.63 USD |
| 7/20/2026 | 71.64 USD |
Bio-Techne Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Bio-Techne Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.56 | 0.64 | 0.71 | 0.74 | 0.93 | 1.11 | 1.14 | 1.16 | 1.22 | 1.22 | 1.27 | 1.39 | 1.57 | 1.72 | 1.96 |
| 10.40 | 12.83 | 14.03 | 11.21 | 3.36 | 26.15 | 18.69 | 2.81 | 2.02 | 5.18 | -0.33 | 4.36 | 9.62 | 13.17 | 9.03 | 14.46 |
| 67.33 | 66.43 | 67.29 | 66.25 | 65.45 | 67.88 | 68.42 | 67.69 | 66.35 | 64.81 | 65.76 | 65.76 | 65.76 | 65.76 | 65.76 | 65.76 |
| 0.34 | 0.37 | 0.43 | 0.47 | 0.48 | 0.63 | 0.76 | 0.77 | 0.77 | 0.79 | 0.80 | 0.83 | 0.91 | 1.03 | 1.13 | 1.29 |
| 150.00 | 121.00 | 136.00 | 125.00 | 176.00 | 237.00 | 307.00 | 306.00 | 206.00 | 106.00 | 251.00 | 389.00 | 436.00 | 522.00 | 474.00 | 398.00 |
| 30.06 | 21.49 | 21.18 | 17.51 | 23.85 | 25.46 | 27.78 | 26.94 | 17.77 | 8.70 | 20.66 | 30.68 | 31.37 | 33.18 | 27.64 | 20.28 |
| 104.00 | 77.00 | 125.00 | 96.00 | 229.00 | 140.00 | 272.00 | 285.00 | 168.00 | 73.00 | 181.00 | 328.00 | 373.00 | 428.00 | 392.00 | – |
| -2.80 | -25.96 | 62.34 | -23.20 | 138.54 | -38.86 | 94.29 | 4.78 | -41.05 | -56.55 | 147.95 | 81.22 | 13.72 | 14.75 | -8.41 | – |
| 1.60 | 1.28 | 1.28 | 1.28 | 1.28 | 1.60 | 1.28 | 0.40 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | – | – |
| 25.00 | -20.00 | – | – | – | 25.00 | -20.00 | -68.75 | -20.00 | – | – | – | – | – | – | – |
| 149.91 | 151.70 | 154.99 | 158.20 | 161.03 | 164.83 | 161.75 | 160.06 | 160.63 | 157.00 | 157.01 | 157.01 | 157.01 | 157.01 | 157.01 | 157.01 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Bio-Techne generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bio-Techne retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bio-Techne's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Bio-Techne has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bio-Techne's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Bio-Techne stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Bio-Techne Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Bio-Techne business model & stock analysis
Bio-Techne SWOT Analysis
Strengths
[ { "text": "Strong", "heading": "1." }, { "text": "Robust", "heading": "2." }, { "text": "Established", "heading": "3." }, { "text": "Strong", "heading": "4." } ]
Weaknesses
[ { "text": "Reliance", "heading": "1." }, { "text": "Limited", "heading": "2." }, { "text": "High", "heading": "3." }, { "text": "Potential", "heading": "4." } ]
Opportunities
[ { "text": "Growing", "heading": "1." }, { "text": "Expansion", "heading": "2." }, { "text": "Acquisitions", "heading": "3." }, { "text": "Increasing", "heading": "4." } ]
Threats
[ { "text": "Economic", "heading": "1." }, { "text": "Intellectual", "heading": "2." }, { "text": "Rapid", "heading": "3." }, { "text": "Regulatory", "heading": "4." } ]
Bio-Techne Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Bio-Techne Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Bio-Techne historical P/E ratio, EBIT multiple, and P/S ratio
Bio-Techne annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Bio-Techne shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Bio-Techne stock splits
Bio-Techne Dividend History
19 years of dividend payments
Bio-Techne dividend history and estimates
Max
Details
Bio-Techne dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Bio-Techne forecasts and price targets in September 2026
Analyst Price Targets 2026Bio-Techne Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/13/2026 | Downgrade | OverweightEqual Weight | 55 | |
| 7/9/2026 | Downgrade | OutperformSector Perform | 49 | |
| 6/30/2026 | Downgrade | BuyHold | 60 | |
| 6/30/2026 | Downgrade | BuyHold | 72 | |
| 6/29/2026 | Downgrade | BuyNeutral | 48 | |
| 6/26/2026 | Downgrade | OutperformMarket Perform | – | |
| 6/26/2026 | Downgrade | OverweightEqual Weight | 67 | |
| 6/26/2026 | Maintained | Neutral | 62 | |
| 5/7/2026 | Maintained | Overweight | 55 | |
| 5/7/2026 | Maintained | In Line | 62 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Bio-Techne Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/11/2026 | 0.53USD | - | 320.97 MUSD | - | 2026 Q4 |
| 5/6/2026 | 0.55USD | - | 323.43 MUSD | - | 2026 Q3 |
| 2/4/2026 | 0.44USD | - | 295.99 MUSD | - | 2026 Q2 |
| 5/1/2024 | 0.50USD | - | 311.61 MUSD | - | 2024 Q3 |
| 1/31/2024 | 0.42USD | - | 283.69 MUSD | - | 2024 Q2 |
| 8/2/2023 | 2.42USD | - | 330.35 MUSD | - | 2023 Q4 |
| 5/2/2023 | 2.31USD | - | 320.99 MUSD | - | 2023 Q3 |
| 1/30/2023 | 1.99USD | - | 296.47 MUSD | - | 2023 Q2 |
| 11/1/2022 | 1.87USD | - | 285.96 MUSD | - | 2023 Q1 |
| 8/4/2022 | 2.12USD | - | 291.43 MUSD | - | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Bio-Techne stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Bio-Techne shareholder structure
| % | Name |
|---|---|
7.67890% | |
6.37359% | |
5.34250% | |
4.94620% | |
4.05739% | |
3.67425% |
Bio-Techne Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
18.00% | SEC ↗ | |
11.27% | SEC ↗ | |
11.00% | SEC ↗ | |
8.70% | SEC ↗ | |
7.38% | SEC ↗ | |
7.20% | SEC ↗ | |
7.00% | SEC ↗ | |
5.90% | SEC ↗ | |
5.80% | SEC ↗ | |
5.46% | SEC ↗ |
Bio-Techne Executives and Management Board
15 members · avg. age 61 · 27 % women
Mr. Kim Kelderman (58)
President, Chief Executive Officer, Director · since 2018
8.15 M USD
Management
Mr. James Hippel (54)
Chief Financial Officer, Executive Vice President - Finance
Mr. William Geist (56)
President - Protein Sciences
Dr. Matthew Mcmanus (56)
President - Diagnostics and Spatial Biology
Mr. Shane Bohnen (50)
Senior Vice President, General Counsel, Corporate Secretary
Mr. David Clair
Investor Relations · since 2016
Board of Directors
Mr. Robert Baumgartner (69)
Independent Chairman of the Board
Mr. John Higgins (55)
Independent Director
Ms. Julie Bushman (64)
Independent Director
Dr. Roeland Nusse (74)
Independent Director
Dr. Alpna Seth (62)
Independent Director
Dr. Joseph Keegan (72)
Independent Director
Bio-Techne Supply Chain
Bio-Techne Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.89 | 0.83 | 0.90 | ||
| 2 | 0.55 | -0.08 | 0.79 | ||
| 3 | 0.83 | 0.38 | 0.77 | ||
| 4 | 0.66 | 0.66 | 0.68 | ||
| 5 | 0.55 | 0.66 | 0.41 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.85 | 0.75 | — | ||
| 2 | 0.86 | 0.79 | — | ||
| 3 | 0.74 | 0.88 | — | ||
| 4 | 0.75 | 0.57 | — | ||
| 5 | — | — | — |
Frequently asked questions about Bio-Techne
Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.
Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.
Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.
Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.
Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.
Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.
Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.
Analysts currently set an average price target of 71.44 USD for the Bio-Techne stock (median: 71.40 USD), implying -1.2 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Bio-Techne stock: 18 recommend buying, 5 holding and 0 selling.
Converted at the current exchange rate, the Bio-Techne share trades at 62.42 EUR (72.30 USD).
The Bio-Techne share (TECH) is listed on 4 stock exchanges, including: NASDAQ (TECH), Frankfurt (TE1.F), München (TE1.MU), Düsseldorf (TE1.DU).
Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.
The revenue of Bio-Techne is 1.22 B USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Bio-Techne is 181.86 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bio-Techne is currently 62.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio-Techne stock.
The price-to-sales ratio (P/S) of Bio-Techne is currently 9.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bio-Techne stock.
The Eulerpool Quality Score for Bio-Techne is 5/10.
The ISIN of Bio-Techne is US09073M1045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bio-Techne is A12ENG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bio-Techne is TECH. The ticker symbol is used to trade Bio-Techne shares on the stock exchange.
Over the past 12 months, Bio-Techne paid a dividend of 0.32 USD . This corresponds to a dividend yield of about 0.44 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.32 USD.
The current dividend yield of Bio-Techne is 0.44 %.
Bio-Techne pays a dividend, distributed in the months of , , , .
Bio-Techne paid dividends every year for the past 18 years.
For the upcoming 12 months, dividends amounting to 0.32 USD are expected. This corresponds to a dividend yield of 0.44 %.
Bio-Techne is assigned to the 'Health' sector.
To receive the latest dividend of Bio-Techne from amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Bio-Techne distributed 0.32 USD as dividends.
The dividends of Bio-Techne are distributed in USD.
Bio-Techne stock
Bio-Techne Peer Group
Bio-Techne Ticker
Bio-Techne FIGI
All fundamentals and in-depth analysis of Bio-Techne
Our stock analysis for Bio-Techne stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.